PD1/PDL1 Inhibitors Market by Product type (Nivolumab, Pembrolizumab, Atezolizumab, Avelumab, Durvalumab), Indication (Melanoma, Non-Small Cell Lung Cancer (NSCLC), Renal Cell Carcinoma (RCC)), Distribution Channel & Region - Forecast to 2020-2030
PD1-PDL1 Inhibitors Market - Analysis, Outlook, Growth, Trends, Forecasts
- October 2020
- 209 pages
Cancer is increasingly being viewed as a major threat to human life, with a high mortality rate. In addition, people around the world are increasingly suffering from a wide variety of cancer. This in turn has resulted in increased investments towards research for the development of treatments for these ailments such as immune checkpoint proteins.
Programmed cell death protein 1/ programmed cell death ligand 1 (PD1/PDL1) inhibitors are rapidly gaining traction in the global healthcare sector in boosting survival rates among cancer patients. The growth of the market can be attributed to minimal toxicity of these products and the faster approvals in terms of safety standards being implemented by regulatory bodies in key regional markets around the world.
Future Market Insights has released a new report which provides readers with critical market insights in terms of revenue, sales, treatment dynamics and innovations for the duration between 2020 and 2030. The coronavirus pandemic is expected to impact short term growth, and pembrolizumab will reflect higher demand with wider scope of cancer treatment applications.
PD-1 Inhibitors to Display Stronger Growth
Surging focus on cancer research, increasing number of approvals, and growing popularity of pembrolizumab and nivolumab among the healthcare community is supporting the demand and application of PD-1 inhibitors.
Also, product approval by bodies such as the Food and Drug Administration (FDA) for treatment of ailments such as head and neck squamous cell cancer, melanoma, and non-small cell lung cancer, and the high prevalence of these diseases are driving adoption of these inhibitors.
While still at a largely nascent stage of adoption in the market, PDL-1 variants are likely to display relatively faster growth, with massive investments made by players in product development towards durvalumab in this segment, creating promising prospects for the industry in the long term.
Research Efforts towards Novel Immunotherapies
However, uncertainties over predictive biomarkers for treating malignant tumors remain a challenge to market players, which has resulted in changes in precision medical approaches and the designs for clinical trials in the field.
Major participants in the PD1/PDL1 inhibitors market are largely focused on the development of novel PD1/PDL1 immunotherapy solutions, which will drive the market in the years ahead. Market players are leveraging the trend and the lucrative benefits of high prices, favorable government policies, and exclusivity of PD1/PDL1 inhibitor offerings in the market.
Research towards diagnostics with antibody production are bolstering adoption rates in the market. Such tech advancements will remain important in terms of commercializing PD1/PDL1 inhibitor offerings being introduced to the market.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
In spite of the impact of the coronavirus pandemic, long-term growth prospects of the PD1/PDL1 inhibitors market is very positive through 2030. In the short term, the market is likely to be moderately impacted by the coronavirus pandemic with supply chains issues and transportation delays. Also, the redirection of essential healthcare resources towards covid-19 is limiting applications of PD1/PDL1 inhibitors.
On the other hand, in the long term the high costs of cancer treatments remain a major obstacle in terms of adoption rates. Investments in terms of research and approvals will hurt growth especially in developing countries.
Also, strict regulations required for approval before product launch and the resulting time consuming and cost prohibitive processes limit growth prospects of market players. Also, the potential risks of allergies, infections, inflammation, and other side effects from PD1/PDL1 inhibitors restrict market developments.
North America PD1/PDL1 Inhibitors Market
The North America market for PD1/PDL1 inhibitors is expected to remain the dominant region for the industry through to 2030. Primarily led by demand from the United States, the growth of the market can be largely be attributed to the growing prevalence of ailments such as lung cancer, skin cancer, and other carcinomas.
Also, North America is home to vast population of the elderly, which has made the requirement of PD1/PDL1 inhibitors necessary for increased efficiency in treatments. Also, according to the American Cancer Society, most lung cancer cases in the region are non-small cell lung cancer, accounting for more than 100,000 fatalities.
Further, the North American market is supported by the presence of numerous major market players and the resultant increase in investments for product development which will generate lucrative growth opportunities in the long term.
Request a sample specific to North America market
Europe PD1/PDL1 Inhibitors Market
Following North America, Europe is the second largest market for PD1/PDL1 inhibitors, and is estimated reflecting very strong growth to reach a valuation of over US$ 33 billion by the end of 2030. Germany is estimated to reflect relatively faster growth than other countries in the region, supported by a large number of clinical trials being conducted relevant to the industry.
Bodies such as the European Medicines Agency has increased focus towards PD1/PDL1 inhibitors in terms of combination treatments and for monotherapy applications, aimed not only towards treatment of ailments in adults but also in trials for pediatric use.
The PD1/PDL1 inhibitors market is gaining traction in the European market with growing awareness about the low toxicity levels and compliance of PD1/PDL1 inhibitors with key healthcare safety regulations implemented in the region.
Request a sample specific to Europe market
East Asia PD1/PDL1 Inhibitors Market
East Asia is a high potential region for players in the PD1/PDL1 inhibitors market. The region has been projected to reflect a higher growth rate than western markets, albeit still being at a nascent stage of growth.
The market, led by China is expected to generate a number of lucrative opportunities for market participants, driven by a massive population, and major investments from public and private sectors into health care infrastructure modernization.
Also, the rise in the number of cancer cases, coupled with the demand for immune check point inhibitors will support the prospects of the market in the long term. However, problems in terms of reimbursement will hurt growth in the industry here.
Pembrolizumab Witnesses Higher Demand
PD1/PDL1 inhibitors are produced in 5 key variants including nivolumab, pembrolizumab, atezolizumab, avelumab, and durvalumab. Of these, the demand for pembrolizumab has been projected to remain relatively higher than the others throughout the assessment period.
The higher demand for pembrolizumab can be largely be attributed to the approval of the inhibitor by regulators for applications in treating a wider range of cancers. Nivolumab will also reflect fast growth for use in multiple cancer treatments.
Non-Small Cell Lung Cancer Treatment Drives Revenue
PD1/PDL1 inhibitors primarily find use in treating a wide range of cancer types. The prominent indications for the use of these inhibitors include melanoma, non-small cell lung cancer, renal cell carcinoma, head and neck squamous cell cancer, bladder cancer, and Merkel cell carcinoma.
Of these cancer types, non-small cell lung cancer is the predominant use of PD1/PDL1 inhibitors. The demand can be attributed to advances in platinum-based chemotherapy and efforts made towards personalized cancer treatments in the sector.
Hospital Pharmacies Critical for Distribution
PD1/PDL1 inhibitors are primarily distributed to cancer patients and healthcare professionals through hospital pharmacies, retail pharmacies, and online pharmacies. The distribution through hospital pharmacies will be the primarily access channel for end users through 2030.
The growth of the hospital pharmacy distribution channel can be attributed to the robust supply chains, large scale orders, and efforts by hospital facilities to maintain large scale inventories for cancer treatment applications.
The manufacturers in the PD1/PDL1 inhibitors market are investing increased resources to towards product development, approval, and launch strategies in a largely consolidated industry. Further, market players are also reflecting interest in capacity expansions, partnerships, and acquisitions to consolidate their market position.
The coronavirus crisis is hurting the short-term prospects of the PD1/PDL1 inhibitors market owing to limited production and delays in logistics and transportation and the prioritization of healthcare resources by medical organizations and regulators towards handling the pandemic, limiting adoption especially in developing countries. However, the demand for cancer treatments and prevention will support the rise of the industry in the long term.
Merck & Co. Inc. in collaboration with Eisai has revealed promising results from two clinical trials, which has been conducted under the clinical program LEAP in terms of anti-pd1/pdl-1 therapy for advanced and unresectable melanoma, colorectal cancer, breast cancer, gastric cancer, and ovarian cancer.
Sanofi has also collaborated with Regeneron Pharmaceuticals to present promising results from a phase 2 clinical trial of the company’s Libtayo pd-1 inhibitor for treating patients suffering from basal cell carcinoma, who had reached an advanced state of the disease or those who could not tolerate hedgehog inhibitor therapy.
AstraZeneca has announced the development of artificial intelligence tool for drug development in collaboration with GSK, which will aid in the development of pd1/pdl1 inhibitors with a new supercomputer being built by Nvidia for a budget of over US$ 50 million.
Aside from these players in the PD1/PDL1 inhibitors market, other industry participants include:
- Bristol-Myers Squibb
- F.Hoffmann-La Roche AG
- Merck KGaA
- Pfizer Inc.
This list is only indicative – The full list of PD1/PDL1 inhibitors players is available on request.
PD1/PDL1 Inhibitors Industry Report: Scope
Historical Data Available for
USD Million for value
Key Regions Covered
North America, Latin America, Europe, South Asia, East Asia, Oceania, Middle East & Africa
Key Countries Covered
US, Canada, Brazil, Mexico, Argentina, Germany, Italy, France, U.K., Spain, BENELUX, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, South Africa
Key Segments Covered
Product Type, Indication, Distribution Channel, and Region
Key Companies Profiled
Bristol-Myers Squibb, Merck & Co. Inc., F-Hoffmann-La Roche AG, Merck KGaA, Pfizer Inc., AstraZeneca
Market Forecast, brand share analysis, competition intelligence, DROT analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing
Enquiry before Buying
- Is this research conducted by Future Market Insights?
Yes, the research has been conducted by expert analysts of Future Market Insights through a combination of primary research and secondary research. To know more about how the research was conducted, you can speak to research analyst.
- What research methodology is followed by FMI?
FMI follows a methodology that encompasses demand side assessment of the market, and triangulates the same through supply side analysis. This methodology is based on use of standard market structure, methods and definitions.
- Who are the respondents for primary research?
FMI speaks to stakeholders across the spectrum, including C-level executives, distributors, product manufacturers, industry experts. For a full list of primary respondents, please reach out to us.
- What are the sources of secondary research?
FMI conducts extensive secondary research through proprietary databases, paid databases, and information available in the public domain. We refer to industry associations, company press releases, annual reports, investor presentations, and research papers. More information about desk research is available upon request.
- Is a sample of this report available for evaluation?
Yes, you can request a sample and it will be sent to you through an email.
- How can I buy this report?
FMI provides a secure online payment system to buy report seamlessly. You can buy the report securely and safely.
- Non-Small Cell Lung Cancer (NSCLC)
- Renal Cell Carcinoma (RCC)
- Head and Neck Squamous Cell Cancer (HNSCC)
- Bladder Cancer
- Merkel Cell Carcinoma (MCC)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- North America (U.S., Canada)
- Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
- Europe (Germany, Italy, France, U.K., BENELUX, Spain, Russia, Rest of Europe)
- South Asia (India, Thailand, Indonesia, Malaysia, Rest of South Asia)
- East Asia (China, Japan, South Korea)
- Oceania (Australia, New Zealand)
- Middle East & Africa (GCC Countries, Turkey, South Africa, Rest of MEA)